contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


faron-pharmaceuticals-unsurprising-report-keeps-estimates-unchanged

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Antti Siltanen

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

The release regarding Varma’s disclosure does not concern the rules of the Finnish stock exchange. The 5, 10, or 15% thresholds have not been breached. The release states “Non-UK issuer,” so it is a London AIM disclosure notification. They have rules for 3, 4, 5%, etc., disclosures for UK companies, but now non-UK entities have also been interpreted as being subject to this obligation. The threshold was already triggered on Feb 11, 2026. Both the four and three percent marks were crossed. Whether those UK limits are binding for non-UK entities, I am not a lawyer. If they aren’t, it doesn’t matter. If they are, why so late? I’m still not a lawyer. The share issue was announced on Feb 9, 2026. Varma started emptying its tank—which held 5,133,674 shares—by roughly half at the latest on Feb 11, 2026, by selling 2,500,000 shares. Now it has promised to refill it with 1,823,310 issue shares at a price of €911,655. There is no specific info on the trading dates, but the share price was clearly over 50c. On the other hand, their job is to look after collective pension assets, not Faron’s share value, which was perhaps gravitating toward the subscription price in the usual way at first, despite Varma. This is what happened with the one-euro issue as well, until it corrected in a few months. It remains to be seen whether Varma participates beyond its commitment or if they permanently reduce their percentage stake. Bioretec is also organizing a rights issue. A maximum of 1.5 billion new shares is proposed, and they want to raise 5–15 MEUR. Mathematically, that’s 1 euro cent per share, but let’s not make comparisons.

Inderes              FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY - Inderes    Faron Pharmaceuticals Ltd | Company announcement | March 11, 2026 at 10:00:00 EETTR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant...                             Strange moves from the pension company, Varma is dumping shares on retail investors and issues the notification a month late

It speaks to poor management. Buffett noted decades ago that a company’s good management is one of the criteria for considering new investments. Faron’s problem may be that it is somewhat of a family business, and in those, the board’s ability to intervene in questionable or even erroneous practices is sometimes a bit more difficult than in other companies.

Settlement on the Helsinki Stock Exchange is currently T+2 days, so if you bought Faron on Tuesday 10.3., you received subscription rights.

Yep, sorry. I misinterpreted your text and you are right that Antti wrote “today” incorrectly.

Well, did I even claim such a thing? The dates are displayed right above. The subscription right was detached from the share yesterday, 11.3, not today, 12.3. Today is the record date for the subscription rights (T+2), and tomorrow the rights will be credited to the account.

March 13th is no longer the date that determines the right; instead, the stock is already ex-rights on March 11th. On March 13th, the subscription rights are simply recorded in the book-entry accounts for those who already hold the right to them.

Faron Pharmaceuticals

Faron’s H1 report offered no surprises. The company didn’t have any revenue as we expected, and the operating loss was in line with our forecasts. There was no significant new information on...

<p>Faron’s H1 report offered no surprises. The company didn’t have any revenue as we expected, and the operating loss was in line with our forecasts. There was no significant new information on research or business progress, so we are not making any changes to the forecasts in our recently published extensive report. Our valuation relies heavily on a DCF calculation based on risk-adjusted estimates, which produces a present value of the stock that remains unchanged at EUR 2.8. In our view, peer analysis suggests a neutral valuation of the stock.</p> 

	2021	22e	23e
Revenue	0.0	0.0	0.0
growth-%
EBIT (adj.)	-21.1	-22.0	-0.8
EBIT-% (adj.)	-527,700.0 %	-550,000.0 %	-19,500.0 %
EPS (adj.)	-0.38	-0.39	-0.02
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Faron Pharmaceuticals: Unsurprising report keeps estimates unchanged

Login required

Key Estimate Figures08.08.2022

Forum discussions